WT1 peptide cancer vaccine.
Wilms'tumor gene 1(WT1) is a leukemia cell-specific marker, and WT1 protein is pan- tumor-associated antigen (TAA) that was ranked as a top among 75 TAAs. WT1 peptide vaccine has been performing for over 800 patients with 58 kinds of malignancies including leukemia and various types of solid tumors. Clinical results are promising, and adverse effects are limited to skin eruption on the vaccine injection sites. Two types of WT1 peptide vaccines are under clinical studies by pharmaceutical companies for the development of medicine.